Conversely, ADRB2 antagonists have been shown to increase the expression of SNCA, leading to increased oxidative stress in mitochondria, dopaminergic neurodegeneration, and an elevated risk for PD [9]. This evidence concerns the gene ADRB2 and Parkinson disease.